Growth in juvenile idiopathic arthritis: The role of inflammation

Clinical and Experimental Rheumatology

Volumn 29, Issue 1, 2011, Pages 104-110

  Gaspari, Stefania ^a   Marcovecchio, M Loredana ^a   Breda, Luciana ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cytokines; Growth; Inflammation; Juvenile idiopathic arthritis

Indexed keywords

CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; GROWTH HORMONE;

CHILD GROWTH; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; GROWTH ACCELERATION; GROWTH DISORDER; GROWTH HORMONE RELEASE; GROWTH INHIBITION; GROWTH PLATE; GROWTH RETARDATION; HUMAN; IMMOBILIZATION; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ADOLESCENT; CHILD; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNOVITIS;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CYTOKINES; GROWTH DISORDERS; GROWTH HORMONE; GROWTH PLATE; HUMANS; SYNOVITIS;

EID: 79955651655     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. th ed. Philadelphia, USA: WB Saunders, 2001, p. 218-21.
2. GÄRE BA: Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 1999; 17: 367-74.
3. SOUZA LS, MACHADO SH, BRENOL CV, BRENOL JC, XAVIER RM: Growth velocity and Interleukin 6 Concentrations in Juvenile Idiopathic Arthritis. J Rheumatol 2008; 35: 2265-71.
4. MACRAE VE, WONG SC, FARQUHARSON C, AHMED SF: Cytokine actions in growth disorders associated with paediatric chronic inflammatory diseases. Int J Mol Med 2006; 18: 1011-8.
5. SIMON D: Puberty in chronically diseased patients. Horm Res 2002; 57 (Suppl. 2): 53-56.
6. REINECKE M, SCHMID AC, HEYBERGERMEYER B, HUNZIKER EB, ZAPF J: Effect of Growth Hormone and Insulin-Like Growth Factor I (IGF-I) on the Expression of IGFI Messenger Ribonucleic Acid and Peptide in Rat Tibial Growth Plate and Articular Chondrocytes in Vivo. Endocrinology 2000; 141: 2847-53.
7. DE BENEDETTI F, MEAZZA C, OLIVERI M et al.: Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001; 142: 4818-26.
8. SIMON D, FERNANDO C, CZERNICHOW P, PRIEUR AM: Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002; 29: 1296-300.
9. SIMON D, LUCIDARME N, PRIEUR A-M, RUIZ J-C, CZERNICHOW P: Treatment of growth failure in juvenile chronic arthritis. Horm Res 2002; 58: 28-32.
10. LIEM JJ, ROSEMBERG AM: Growth patterns in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: 663-8.
11. ZAK M, MULLER J, PEDERSEN FK: Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis: a long-term follow-up study. Horm Res 1999; 26: 99-103.
12. WANG SJ, YANG YH, LIN YT et al.: Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 2002; 21: 363-8.
13. ANSELL BM, BYWATERS E: Growth in Still's disease. Ann Rheum Dis 1956; 15: 295-319.
14. SAHA MT, VERRONEN P, LAIPPALA P, LENKO HL: Growth of prepubertal children with juvenile chronic arthritis. Acta Pediatr 1999; 88: 724-8.
15. MACRAE VE, AHMED SF, FARQUHARSON C: The pathophysiology of the growth plate in juvenile idiopathic arthritis. Rheumatology (Oxford) 2006; 45: 11-9.
16. KUTUKCULER N, CAGLAYAN S, AYDOGDU F: Study of proinflammatory (TNF-alpha, IL-1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters. Clin Rheumatol 1998; 17: 288-92.
17. MACRAE VE, FARQUHARSON C, AHMED SF: The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to proinflammatory cytokines. J Endocrinol 2006; 189: 319-28.
18. MARTENSSON K, CHRYSIS D, SAVENDAHL L: Interleukin-1 beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004; 19: 1805-12.
19. YOKOTA S: Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003; 15: 581-6.
20. DE BENEDETTI F, MEAZZA C, MARTINI A: Role of interleukin-6 in growth failure: an animal model. Horm Res 2002; 58 (Suppl. 1): 24-7.
21. OU LS, SEE LC, WU CJ, KAO CC, LIN YL, HUANG JL: Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol 2002; 21: 52-6.
22. DE BENEDETTI F, ALONZI T, MORETTA A et al.: Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-50.
23. DE BENEDETTI F, MEAZZA C, OLIVERI M et al.: Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001; 142: 4818-26.
24. ARANY E, AFFORD S, STRAIN AJ, WINWOOD PJ, ARTHUR MJ, HILL DJ: Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994; 79: 1871-6.
25. GERBER A, WILLE A, WELTE T, ANSORGE S, BUHLING F: Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells. J Interferon Cytokine Res 2001; 21: 11-9.
26. BARILLE S, COLLETTE M, THABARD W, BLEUNVEN C, BATAILLE R, AMIOT M: Soluble IL-6Rα upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells. Cytokine 2000; 12: 1426-9.
27. DAVIES UM, ROONEY M, PREECE MA, ANSELL BM, WOO P: Treatment of growth-retardation in juvenile chronic arthritis with recombinant human growth-hormone. J Rheumatol 1994; 21: 153-8.
28. LIESKOVSKA J, GUO D, DERMAN E: IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res 2002; 12: 388-98.
29. NAKAJIMA S, NARUTO T, MIYAMAE T et al.: Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells. Cytokine 2009; 47: 91-7.
30. VAN DER EERDEN BC, KARPERIEN M, WIT JM: Systemic and local regulation of the growth plate. Endocr Rev 2003; 24: 782-801.
31. GREEN H, MORIKAWA M, NIXON T: A dual effector theory of growth-hormone action. Differentiation 1985; 29: 195-8.
32. DE BENEDETTI F, RUCCI N, DEL FATTORE A: Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006; 54: 3551-63.
33. DE BENEDETTI F: The impact of chronic inflammation on the growing skeleton: lessons from interleukin-6 transgenic mice. Horm Res 2009; 72 (Suppl. 1): 26-9.
34. LIAN JB, STEIN JL, STEIN GS et al.: Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res 2003; 44 (Suppl. 1): 141-8.
35. KUDO O, SABOKBAR A, POCOCK A, ITONAGA I, FUJIKAWA Y, ATHANSOU NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 1-7.
36. NAKAJIMA S, NARUTO T, MIYAMAE T: Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2009; 19:42-6.
37. SUGIYAMA E: Role of matrix metalloproteinase-3 in joint destruction in rheumatoid arthritis. Clin Calcium 2007; 17: 528-34.
38. CAMOZZI V, TOSSI A, SIMONI E, PAGANI F, FRANCUCCI CM, MORO L: Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest 2007; 30: 13-7.
39. GOLDRING MB, BIRKHEAD J, SANDELL LJ, KIMURA T, KRANE SM: Interleukin-1 suppresses expression of cartilage-specific type-II and type-IX collagens and increases type-Iand type-III collagens in human chondrocytes. J Clin Invest 1988; 82: 2026-37.
40. BATEMAN JF, LAMANDÉ SR, RAMSHAW JAM: Collagen superfamily. In WD COMPER (Ed.): Extracellular Matrix, vol. 2,. Amsterdam, The Netherlands: Harvood Academic Publishers 1996, pp 22-67.
41. MANGGE H, KENZIAN H, GALLISTL S: Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38: 211-20.
42. ANDERSEN NA, LARSEN CM, MANDRUPPOULSEN T: TNF-alpha and IFN-gamma potentiate IL-1beta induced mitogen activated protein kinase activity in rat pancreatic islets of Langerhans. Diabetologia 2000; 43: 1389-96.
43. KATO Y, NAKASHIMA K, IWAMOTO M et al.: Effects of interleukin-1 on syntheses of alkaline-phosphatase, type-x collagen, and 1,25-dihydroxyvitamin-d(3) receptor, and matrix calcification in rabbit chondrocyte cultures. J Clin Invest 1993; 92: 2323-30.
44. AIZAWA T, KON T, EINHORN TA, GERSTENFELD LC: Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res 2001; 19: 785-96.
45. HORIGUCHI M, AKIYAMA H, ITO H, SHIGENO C, NAKAMURA T: Tumour necrosis factor-alpha up-regulates the expression of BMP-4 mRNA but inhibits chondrogenesis in mouse clonal chondrogenic EC cells, ATDC5. Cytokine 2000; 12: 526-30.
46. VAN BEZOOIJEN RL, VAN DER WEE-PALS L, PAPAPOULOS SE, LOWIK CWGM: Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 2002; 61: 870-6.
47. CHRYSIS D, ZAMAN F, CHAGIN AS, TAKIGAWA M, SAVENDAHL L: Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3'-kinase signaling pathway. Endocrinology 2005; 146: 1391-7.
48. MUSHTAQ T, BIJMAN P, AHMED SF, FARQUHARSON C: Insulin-like growth factor-I augments chondrocyte hypertrophy and reverses glucocorticoid-mediated growth retardation in fetal mice metatarsal cultures. Endocrinology 2004; 145: 2478-86.
49. BLOUNT S, CRAWFORD A: Regulation of igf-1 receptors on rabbit articular chondrocytes by inflammatory mediators. Agents Actions 1994; 41: C177-9.
50. MATSUMOTO T, TSUKAZAKI T, ENOMOTO H, IWASAKI I, YAMASHITA S: Effects of interleukin-1-beta on insulin-like growth factor-I autocrine/paracrine axis in cultured rat articular chondrocytes. Ann Rheum Dis 1994; 53: 128-33.
51. SHEN WH, ZHOU JH, BROUSSARD SR, FREUND GG, DANTZER R, KELLEY KW: Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 2002; 62: 4746-56.
52. STRLE K, BROUSSARD SR, MCCUSKER RH et al.: Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 2004; 145: 4592-602.
53. BROUSSARD SR, MCCUSKER RH, NOVAKOFSKI JE et al.: IL-1 beta impairs insulin-like growth factor I induced differentiation and downstream activation signals of the insulinlike growth factor I receptor in myoblasts. J Immunol 2004; 172: 7713-20.
54. KOIKE M, YAMANAKA Y, INOUE M, TANAKA H, NISHIMURA R, SEINO Y: Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK, J Bone Miner Res 2003; 18: 2043-51
55. MACRAE VE, AHMED SF, MUSHTAQ T, FARQUHARSON C: IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1β. Growth Horm IGF Res 2007; 17: 435-9.
56. MALEMUD CJ: Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta 2007; 375: 10-9.
57. WOJCIK J, POSTEL-VINAY MC: Signal transduction of the growth hormone (GH) receptor, and GH-binding protein. Growth Horm IGF Res 1999; 9: 51-5.
58. YOSHIZATO H, TANAKA M, NAKAI N, NAKAO N, NAKASHIMA K: Growth hormone (GH)-stimulated insulin-like growth factor I gene expression is tyrosine phosphorylation pathway depending on C-terminal region of human GH human GH receptor-expressing Ba/F3 cells. Endocrinology 2004; 145: 214-20.
59. LICHANSKA AM, WATERS MJ: New insights into growth hormone receptor function and clinical implications. Horm Res 2008; 69: 138-45.
60. DAVEY HW, XIE T, MCLACHLAN MJ, WILKINS RJ, WAXMAN DJ, GRATTAN DR: STAT5b is required for GH-induced liver igf-I gene expression. Endocrinology 2001; 142: 3836-41.
61. SHI H, TZAMELI I, BJORBAEK C, FLIER JS: Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signalling. J Biol Chem 2004; 279: 34733-40.
62. KREBS DL, HILTON DJ: SOCS proteins: Negative regulators of cytokine signalling. Stem Cells 2001; 19: 378-87.
63. HORVAT S, MEDRANO JF: Lack of Socs2 expression causes the high-growth phenotype in mice. Genomics 2001; 72: 209-12.
64. MCINNES IB, GRACIE JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4: 392-7.
65. SMOLEWSKA E, BROZIK H, SMOLEWSKI P, BIERNACKA-ZIELINSKA M, DARZYNKIEWICZ Z, STANCZY J: Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2003; 62: 761-3.
66. BIERBAUM S, SENGLER C, GERHOLD K, BERNER R, HEINZMANN A: Polymorphism within interleukin 15 are associated with juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 24: 219.
67. BASLUND B, TVEDE N, DANNESKIOLDSAMSOE B et al.: Targeting interleukin-15 in patients with rheumatoid arthritis: a proof of concept study. Arthritis Rheum 2005; 59: 2686-92.
68. WONG SC, MACRAE VE, GRACIE JA: Inflammatory cytokines in juvenile idiopathic arthritis: Effects on physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res 2008; 18: 369-78.
69. GOUWY M, STRUYF S, PROOST P, VAN DAMME J: Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev 2005; 16: 561-80.